Abcam, ab96129, Anti-ST3Gal I antibody

Size: 50µL
Rabbit Polyclonal ST3Gal I antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 6 publications. Immunogen corresponding to Recombinant Fragment Protein within Human ST3GAL1 aa 1-200.
Key facts
Host species:Rabbit,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Recombinant Fragment Protein within Human ST3GAL1 aa 1-200. The exact immunogen used to generate this antibody is proprietary information.Q11201

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Immunogen, Storage buffer-pH: 7Preservative: 0.025% Proclin 300Constituents: PBS, 20% Glycerol (glycerin, glycerine), 1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ST3Gal I also known as ST3 beta-galactoside alpha-23-sialyltransferase 1 or sialyltransferase 1 is an enzyme with a molecular mass of approximately 35 kDa. This enzyme catalyzes the transfer of sialic acid from CMP-sialic acid to galactose-containing substrates specifically creating the sialyl T antigen. ST3Gal I is expressed in many tissues including the gastrointestinal tract lungs and the immune system reflecting its diverse roles in different physiological contexts.
Biological function summary
ST3Gal I participates in glycosylation processes that modify proteins and lipids influencing cell-cell interactions immune responses and protein stability. It often associates with glycosylation complexes ensuring the proper addition of sialic acid to glycoconjugates. These modifications are critical for the formation of sialyated glycoconjugates which play significant roles in cellular communication and pathogen recognition.
Pathways
ST3Gal I impacts the sialylation pathway and by extension affects glycan biosynthesis pathways. It modifies glycoproteins and glycolipids which are important in cell adhesion and signaling pathways. Within these pathways ST3Gal I shows interactions with proteins involved in these processes such as those in the selectin family which mediate leukocyte trafficking.
Altered ST3Gal I expression or activity links to certain cancers and immune disorders. Its dysregulation can lead to aberrant glycosylation patterns impacting processes like tumor metastasis and immune evasion. For instance the sialylation of mucins which influences tumor progression requires ST3Gal I. Also its interaction with other glycosyltransferases includes the regulation of immune cell surface antigens connecting it to autoimmune conditions.